Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor

Katarina Steen Carlsson; Jan Astermark; Sharyne Donfield; Erik Berntorp

doi:10.1160/TH07-11-0698

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(06): 1060-1067
DOI: 10.1160/TH07-11-0698

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor

Authors

Katarina Steen Carlsson

¹Lund University Centre for Health Economics, LUCHE; and the Vårdal Institute for Health Sciences, Lund, Sweden
Jan Astermark

²Department of Haematology and Coagulation Disorders, Malmö University Hospital, Malmö, Sweden
Sharyne Donfield

³Department of Biostatistics, Rho Inc., Chapel Hill, North Carolina, USA
Erik Berntorp

²Department of Haematology and Coagulation Disorders, Malmö University Hospital, Malmö, Sweden

Abstract

Summary

The development of inhibitory antibodies to factor VIII is a serious complication of haemophilia. Two haemostatic agents with different bypassing mechanisms have been used in the treatment of patients with inhibitors: activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa). The objective was to compare cost and outcome of aPCC and rFVIIa in the treatment of joint bleeds. The analyses were based on the FENOC (FEIBA NovoSeven Comparative Study) crossover study where 48 patients used aPCC and rFVIIa to treat two joint bleeds. Incremental cost-effectiveness ratios were calculated for three outcome measures and the variation in cost was analyzed using two alternative regression methods. Results were subjected to sensitivity analyses. Key determinants of cost were prescribed dose, bodyweight and treatment in addition to protocol.The cost of aPCC was on average lower than rFVIIa. At all but one time point, patients rated slightly higher (but not statistically significantly) percentages of treatment efficacy and stopping of the bleed by aPCC. The reported reduction in pain from start of treatment up to 48 hours varied considerably among individuals. The different relative prices in the US, Turkey and Sweden mattered, but did not reverse the main results. In conclusion, the cost per episode was significantly lower for aPCC. The large individual-level variation in reduction of pain supports decisions that consider the individual patient’s experience and that accept trade-offs between cost and reduction in pain rather than focusing on cost only.

Keywords

Haemophilia A/B - factor VIII inhibitors - costs and cost analysis - bypassing agents - incremental cost-effectiveness

Volltext

Referenzen

References
1 Turecek P, Varadi K, Gritsch H. et al. FEIBA: mode of action. Haemophilia 2004; 10 (Suppl. 02) 3-9.
2 Hoffman M, Monroe DI. The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis. Disease-a-Month 2003; 49: 14-21.
3 Steen Carlsson K, Höjgård S, Lethagen S. et al. Economic evaluation: What are we looking for and how do we get there?. Haemophilia 2004; 10 (Suppl. 01) 44-49.
4 Hughes M, Lip G. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
5 Aledort L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-1708.
6 Sjamsoedin L, Heijnen L, Mauser-Bunschoten E. et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-721.
7 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
8 Pruthi R, Mathew P, Valentino L. et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-732.
9 Joshi AV, Stephens JM, Munro V. et al. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006; 22: 23-31.
10 Odeyemi IA, Guest JF. Modelling the economic impact of recominant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK. J Med Econ 2002; 5: 119-133.
11 Putnam KG, Bohn RL, Ewenstein BM. et al. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and hightitre inhibitors. Haemophilia 2005; 11: 261-269.
12 Astermark J, Donfield SM, DiMichele DM. et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novo-Seven Comparative (FENOC) Study. Blood 2007; 109: 546-551.
13 Hilgartner M, Knatterud G. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
14 Key NS, Aledort LM, Beardsley D. et al. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. Thromb Haemost 1998; 80: 912-918.
15 Parameswaran R, Shapiro A, Gill JC. et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-106.
16 2005 Red Book. Vol 109. Thomson Healthcare. 2005 .
17 Läkemedelsförmånsnämnden (Swedish Pharmaceutical Benefits Board). Price database for year 2006.. Available at: http://www.lfn.se Accessed February 10, 2006.
18 Türkiye Cumhuriyeti Sa¢lik Bakanli¢i (Ministry of Health of Turkey). Yili Fiyat Listeleri. Division of Pharmaceuticals (Ilac Eczacilik Genel Mudurlugu – IEGM). 2005 Available at http://www.saglik.gov.tr/IEGM/BelgeGoster.aspx?F6E10F8892433CFF71BE64510F6C8BC91084D1ED2B222F12 Accessed April 3, 2007.
19 Altman DG.. Practical statistics for medical research. Chapman & Hill; London: 1991. .
20 Greene W.. Econometric analysis. Fourth edition ed.. Prentice Hall International, Inc.; Upper Saddle River, New Jersey: 2000. .
21 Drummond M, Sculpher M, Torrance G. et al. Methods for the economic evaluation of health care programmes. Third edition ed.. Oxford University Press; Oxford: 2005. .
22 StataCorp. Stata Statistical Software: Release 8.0. Stata Corporation. College Station, Texas: 2003. .
23 Lee M, Lusher J. The problem of therapeutic equivalence with paired qualitative data: an example from a clinical trial using haemophiliacs with an inhibitor to factor VIII. Statistics Med 1991; 10: 433-441.
24 Hilgartner M, Aledort L, Andes A. et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-630.
25 Negrier C, Goudemand J, Sultan Y. et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Stuudy Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-1119.
26 Santagostino E, Mancuso M, Rocino A. et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-371.